Close Menu

NEW YORK (360Dx) – OraSure Technologies announced after the close of the market on Wednesday an 8 percent year-over-year increase in its second quarter revenues on strong international sales of its OraQuick HIV testing products.

For the three-month period ended June 30, OraSure's revenues rose to $43.6 million from $40.2 million in the same quarter last year, topping Wall Street's consensus estimate of $42.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.